Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions

David R. Elmaleh, Martin R. Farlow, Peter S. Conti, Ronald G. Tompkins, Ljiljana Kundakovic, Rudolph E. Tanzi

Research output: Contribution to journalReview article

Abstract

Alzheimer's disease (AD) clinical trials, focused on disease modifying drugs and conducted in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach efficacy endpoints in improving cognitive function in most cases to date or have been terminated due to adverse events. Drugs that have reached clinical stage were reviewed using web resources (such as clinicaltrials.gov, alzforum.org, company press releases, and peer reviewed literature) to identify late stage (Phase II and Phase III) efficacy clinical trials and summarize reasons for their failure. For each drug, only the latest clinical trials and ongoing trials that aimed at improving cognitive function were included in the analysis. Here we highlight the potential reasons that have hindered clinical success, including clinical trial design and choice of outcome measures, heterogeneity of patient populations, difficulties in diagnosing and staging the disease, drug design, mechanism of action, and toxicity related to the long-term use. We review and suggest approaches for AD clinical trial design aimed at improving our ability to identify novel therapies for this devastating disease.

Original languageEnglish (US)
Pages (from-to)715-732
Number of pages18
JournalJournal of Alzheimer's Disease
Volume71
Issue number3
DOIs
StatePublished - Jan 1 2019

Fingerprint

Alzheimer Disease
Clinical Trials
Cognition
Pharmaceutical Preparations
Phase III Clinical Trials
Aptitude
Drug Design
Population Characteristics
Therapeutics
Outcome Assessment (Health Care)
Direction compound

Keywords

  • Alzheimer's disease
  • amyloid-β
  • biomarkers
  • clinical trial design
  • combined modality therapy
  • inflammation
  • selection of subjects
  • tau protein
  • treatment outcomes

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Developing Effective Alzheimer's Disease Therapies : Clinical Experience and Future Directions. / Elmaleh, David R.; Farlow, Martin R.; Conti, Peter S.; Tompkins, Ronald G.; Kundakovic, Ljiljana; Tanzi, Rudolph E.

In: Journal of Alzheimer's Disease, Vol. 71, No. 3, 01.01.2019, p. 715-732.

Research output: Contribution to journalReview article

Elmaleh, David R. ; Farlow, Martin R. ; Conti, Peter S. ; Tompkins, Ronald G. ; Kundakovic, Ljiljana ; Tanzi, Rudolph E. / Developing Effective Alzheimer's Disease Therapies : Clinical Experience and Future Directions. In: Journal of Alzheimer's Disease. 2019 ; Vol. 71, No. 3. pp. 715-732.
@article{26dc2aaaad9d428fa33aaff70e5987d2,
title = "Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions",
abstract = "Alzheimer's disease (AD) clinical trials, focused on disease modifying drugs and conducted in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach efficacy endpoints in improving cognitive function in most cases to date or have been terminated due to adverse events. Drugs that have reached clinical stage were reviewed using web resources (such as clinicaltrials.gov, alzforum.org, company press releases, and peer reviewed literature) to identify late stage (Phase II and Phase III) efficacy clinical trials and summarize reasons for their failure. For each drug, only the latest clinical trials and ongoing trials that aimed at improving cognitive function were included in the analysis. Here we highlight the potential reasons that have hindered clinical success, including clinical trial design and choice of outcome measures, heterogeneity of patient populations, difficulties in diagnosing and staging the disease, drug design, mechanism of action, and toxicity related to the long-term use. We review and suggest approaches for AD clinical trial design aimed at improving our ability to identify novel therapies for this devastating disease.",
keywords = "Alzheimer's disease, amyloid-β, biomarkers, clinical trial design, combined modality therapy, inflammation, selection of subjects, tau protein, treatment outcomes",
author = "Elmaleh, {David R.} and Farlow, {Martin R.} and Conti, {Peter S.} and Tompkins, {Ronald G.} and Ljiljana Kundakovic and Tanzi, {Rudolph E.}",
year = "2019",
month = "1",
day = "1",
doi = "10.3233/JAD-190507",
language = "English (US)",
volume = "71",
pages = "715--732",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Developing Effective Alzheimer's Disease Therapies

T2 - Clinical Experience and Future Directions

AU - Elmaleh, David R.

AU - Farlow, Martin R.

AU - Conti, Peter S.

AU - Tompkins, Ronald G.

AU - Kundakovic, Ljiljana

AU - Tanzi, Rudolph E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Alzheimer's disease (AD) clinical trials, focused on disease modifying drugs and conducted in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach efficacy endpoints in improving cognitive function in most cases to date or have been terminated due to adverse events. Drugs that have reached clinical stage were reviewed using web resources (such as clinicaltrials.gov, alzforum.org, company press releases, and peer reviewed literature) to identify late stage (Phase II and Phase III) efficacy clinical trials and summarize reasons for their failure. For each drug, only the latest clinical trials and ongoing trials that aimed at improving cognitive function were included in the analysis. Here we highlight the potential reasons that have hindered clinical success, including clinical trial design and choice of outcome measures, heterogeneity of patient populations, difficulties in diagnosing and staging the disease, drug design, mechanism of action, and toxicity related to the long-term use. We review and suggest approaches for AD clinical trial design aimed at improving our ability to identify novel therapies for this devastating disease.

AB - Alzheimer's disease (AD) clinical trials, focused on disease modifying drugs and conducted in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach efficacy endpoints in improving cognitive function in most cases to date or have been terminated due to adverse events. Drugs that have reached clinical stage were reviewed using web resources (such as clinicaltrials.gov, alzforum.org, company press releases, and peer reviewed literature) to identify late stage (Phase II and Phase III) efficacy clinical trials and summarize reasons for their failure. For each drug, only the latest clinical trials and ongoing trials that aimed at improving cognitive function were included in the analysis. Here we highlight the potential reasons that have hindered clinical success, including clinical trial design and choice of outcome measures, heterogeneity of patient populations, difficulties in diagnosing and staging the disease, drug design, mechanism of action, and toxicity related to the long-term use. We review and suggest approaches for AD clinical trial design aimed at improving our ability to identify novel therapies for this devastating disease.

KW - Alzheimer's disease

KW - amyloid-β

KW - biomarkers

KW - clinical trial design

KW - combined modality therapy

KW - inflammation

KW - selection of subjects

KW - tau protein

KW - treatment outcomes

UR - http://www.scopus.com/inward/record.url?scp=85073080132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073080132&partnerID=8YFLogxK

U2 - 10.3233/JAD-190507

DO - 10.3233/JAD-190507

M3 - Review article

C2 - 31476157

AN - SCOPUS:85073080132

VL - 71

SP - 715

EP - 732

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -